Compugen Ltd (CGEN)
Compugen Ltd. (NASDAQ:CGEN) Q1 2026 Earnings Call Transcript May 18, 2026Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $-0.07. In this article, we will ...
Model output · Signal date 2026-10-14
Compugen Ltd (CGEN) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
Total
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Middle 30%
of 5379 stocks scored
Rank correlation · 90D
n/a
No per-ticker sample yet
Market Cap
$187M
small-cap · #60 of 60 peers
Summary
Compugen Ltd (CGEN) stock forecast summary
On Oct. 14, 2026, CGEN is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5379 stocks scored that day.
Compugen Ltd is a small-cap company with a market capitalization of $187M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for CGEN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CGEN included.
Follow CGEN freePrice
CGEN price chart and AI forecast
Cross-section · 2026-10-14
How CGEN ranks among 5379 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals
Compugen Ltd (CGEN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | CGEN | Rank |
|---|---|---|
| Market Cap | $187M | 60/60 |
| P/B Ratio | 1.82x | 46/50 |
| EPS | $0.22 | – |
| Book Value/Share | $1.09 | – |
Profitability & Margins
| Metric | CGEN | Rank |
|---|---|---|
| ROE | 20.6% | 6/47 |
| ROA | 13.5% | 6/49 |
| ROIC | 12.3% | 8/50 |
| Gross Margin | 82.9% | 7/22 |
| Operating Margin | 16.3% | 10/37 |
| Net Margin | 21.0% | 6/36 |
| EBT Margin | 25.5% | 8/38 |
| Tax Rate | 17.8% | – |
Financial Health
| Metric | CGEN | Rank |
|---|---|---|
| Current Ratio | 6.56x | 25/54 |
| D/E Ratio | 0.52x | 20/50 |
| Financial Leverage | 1.52x | 20/50 |
| Working Capital | $125M | 50/54 |
Cash Flow
| Metric | CGEN | Rank |
|---|---|---|
| Operating Cash Flow | $81M | 13/52 |
Operational Efficiency
| Metric | CGEN | Rank |
|---|---|---|
| Payables Period | 50 days | 14/23 |
Income Statement
| Metric | CGEN | Rank |
|---|---|---|
| Operating Income | $16M | 12/50 |
| Net Income | $21M | 13/49 |
| R&D Expense | $48M | 48/51 |
| Cost of Goods Sold | $17M | 20/23 |
Dividend & Shareholder Information
| Metric | CGEN | Rank |
|---|---|---|
| Shares Outstanding | 95M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $148M | 94.5% of assets |
| Cash & Short-term Investments | $91M | 57.8% of assets |
| Total Liabilities | $54M | 34.4% of assets |
| Short-term Debt | $20M | 12.9% of assets |
Quarterly Financial Reports
CGEN quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Compugen Ltd (CGEN) industry peers
Companies classified under the same SEC industry code as Compugen Ltd (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| CGEN Compugen Ltd | ▶ | $187M |
| AMGN Amgen Inc | ▼ | $223.19B |
| GILD Gilead Sciences, Inc. | ▶ | $183.41B |
| MRNA Moderna, Inc. | ▲ | $86.33B |
| ARGX Argenx Se | ▼ | $49.67B |
| RVMD Revolution Medicines, Inc. | ▲ | $40.39B |
| BIIB Biogen Inc. | ▼ | $33.79B |
| BNTX Biontech Se | ▶ | $22.51B |
| MESO Mesoblast Ltd | ▶ | $18.02B |
| EXEL Exelixis, Inc. | ▲ | $14.75B |
| NBIX Neurocrine Biosciences Inc | ▼ | $13.74B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $12.44B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| IBRX Immunitybio, Inc. | ▲ | $10.39B |
| PCVX Vaxcyte, Inc. | ▲ | $9.94B |
| RGEN Repligen Corp | ▲ | $9.90B |
| QGEN Qiagen N.V. | ▼ | $9.86B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.51B |
| TWST Twist Bioscience Corp | ▲ | $9.49B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.87B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.57B |
| IMVT Immunovant, Inc. | ▲ | $5.93B |
| KOD Kodiak Sciences Inc. | ▲ | $5.76B |
| CGON Cg Oncology, Inc. | ▲ | $5.53B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.93B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.03B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.80B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.11B |
| DNLI Denali Therapeutics Inc. | ▲ | $2.94B |
| DBVT Dbv Technologies S.A. | ▼ | $2.67B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.52B |
| ADMA Adma Biologics, Inc. | ▲ | $2.31B |
| NVAX Novavax Inc | ▲ | $2.11B |
| VCEL Vericel Corp | ▶ | $2.06B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.05B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.80B |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.71B |
| ALVO Alvotech | ▶ | $1.68B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.48B |
| IMCR Immunocore Holdings Plc | ▶ | $1.43B |
| COAG Hemab Therapeutics Holdings, Inc. | ▲ | $1.39B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.17B |
| REPL Replimune Group, Inc. | ▲ | $1.14B |
| VOR Vor Biopharma Inc. | ▶ | $1.13B |
| JATT Zura Bio Ltd | ▼ | $1000M |
| VALN Valneva Se | ▼ | $965M |
| MGTX Meiragtx Holdings Plc | ▶ | $955M |
| IMTX Immatics N.V. | ▲ | $916M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $907M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $844M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $829M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $792M |
| SANA Sana Biotechnology, Inc. | ▲ | $721M |
| CADL Candel Therapeutics, Inc. | ▲ | $709M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $682M |
| AURA Aura Biosciences, Inc. | ▲ | $650M |
| SLDB Solid Biosciences Inc. | ▲ | $624M |
| PRME Prime Medicine, Inc. | ▲ | $602M |
Where CGEN sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Compugen Ltd (CGEN) stock news
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
Hello, everyone. Welcome to Jones fireside chat with Dr. Eran Ophir, President and CEO of Compugen. I am Danya Ben Hail, an analyst at Jones Research. Compugen was doing computational target discovery ...
FAQ
Compugen Ltd (CGEN) stock forecast FAQ
What is the Compugen Ltd (CGEN) stock forecast?
On Oct. 14, 2026, CGEN is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Compugen Ltd stock predictions?
A per-ticker accuracy statistic for CGEN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Compugen Ltd forecasts updated?
Compugen Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Compugen Ltd's industry peers?
60 issuers in our coverage, CGEN included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.